Mosaic Immunoengineering Stock Performance
| CPMV Stock | USD 1.00 0.00 0.00% |
On a scale of 0 to 100, Mosaic Immunoengineerin holds a performance score of 5. The company secures a Beta (Market Risk) of 0.48, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Mosaic Immunoengineerin's returns are expected to increase less than the market. However, during the bear market, the loss of holding Mosaic Immunoengineerin is expected to be smaller as well. Please check Mosaic Immunoengineerin's jensen alpha, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to make a quick decision on whether Mosaic Immunoengineerin's current price movements will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Mosaic Immunoengineering are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain primary indicators, Mosaic Immunoengineerin showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 352.7 K | |
| Total Cashflows From Investing Activities | 27.6 K |
Mosaic |
Mosaic Immunoengineerin Relative Risk vs. Return Landscape
If you would invest 103.00 in Mosaic Immunoengineering on September 5, 2024 and sell it today you would lose (3.00) from holding Mosaic Immunoengineering or give up 2.91% of portfolio value over 90 days. Mosaic Immunoengineering is currently generating 0.9249% in daily expected returns and assumes 14.5082% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Mosaic, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mosaic Immunoengineerin Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mosaic Immunoengineerin's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Mosaic Immunoengineering, and traders can use it to determine the average amount a Mosaic Immunoengineerin's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0638
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CPMV | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 14.51 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.92 actual daily | 18 82% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 5 95% of assets perform better |
Based on monthly moving average Mosaic Immunoengineerin is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mosaic Immunoengineerin by adding it to a well-diversified portfolio.
Mosaic Immunoengineerin Fundamentals Growth
Mosaic OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Mosaic Immunoengineerin, and Mosaic Immunoengineerin fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mosaic OTC Stock performance.
| Return On Asset | -4.2 | |||
| Current Valuation | 10.22 M | |||
| Shares Outstanding | 7.24 M | |||
| Price To Book | 9.33 X | |||
| EBITDA | (3.52 M) | |||
| Cash And Equivalents | 205.99 K | |||
| Cash Per Share | 0.03 X | |||
| Total Debt | 735.15 K | |||
| Book Value Per Share | (0.60) X | |||
| Cash Flow From Operations | (679.24 K) | |||
| Earnings Per Share | (0.51) X | |||
| Total Asset | 269.49 K | |||
About Mosaic Immunoengineerin Performance
Evaluating Mosaic Immunoengineerin's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Mosaic Immunoengineerin has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mosaic Immunoengineerin has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Mosaic ImmunoEngineering Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. The company was founded in 2020 and is based in Novato, California. Mosaic Immunoengineerin operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.Things to note about Mosaic Immunoengineering performance evaluation
Checking the ongoing alerts about Mosaic Immunoengineerin for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Mosaic Immunoengineering help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mosaic Immunoengineerin is way too risky over 90 days horizon | |
| Mosaic Immunoengineerin has some characteristics of a very speculative penny stock | |
| Mosaic Immunoengineerin appears to be risky and price may revert if volatility continues | |
| Mosaic Immunoengineerin has a very high chance of going through financial distress in the upcoming years | |
| Mosaic Immunoengineering currently holds 735.15 K in liabilities. Mosaic Immunoengineering has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Mosaic Immunoengineerin until it has trouble settling it off, either with new capital or with free cash flow. So, Mosaic Immunoengineerin's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mosaic Immunoengineering sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mosaic to invest in growth at high rates of return. When we think about Mosaic Immunoengineerin's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (3.68 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Mosaic Immunoengineering currently holds about 205.99 K in cash with (679.24 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03. | |
| Roughly 89.0% of the company shares are held by company insiders |
- Analyzing Mosaic Immunoengineerin's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mosaic Immunoengineerin's stock is overvalued or undervalued compared to its peers.
- Examining Mosaic Immunoengineerin's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mosaic Immunoengineerin's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mosaic Immunoengineerin's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Mosaic Immunoengineerin's otc stock. These opinions can provide insight into Mosaic Immunoengineerin's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Mosaic OTC Stock Analysis
When running Mosaic Immunoengineerin's price analysis, check to measure Mosaic Immunoengineerin's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mosaic Immunoengineerin is operating at the current time. Most of Mosaic Immunoengineerin's value examination focuses on studying past and present price action to predict the probability of Mosaic Immunoengineerin's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mosaic Immunoengineerin's price. Additionally, you may evaluate how the addition of Mosaic Immunoengineerin to your portfolios can decrease your overall portfolio volatility.